Table 1.

Senescence inducers: conventional chemotherapy and radiotherapy.

Class	Drug	Cancer	Model
Alkylating agents	Cisplatin	Fibrosarcoma	HT1080 [70]
		Melanoma	A375, B16F10 [71]
		Nasopharyngeal carcinoma	CNE1 [72]
	Cyclophosphamide	B‐cell lymphoma	Eμ‐Myc;ectopic Bcl2 mouse model [73]
	Temozolomide	Glioma	U87MG [74, 75]; GaMG [74]; U87, LN229 [76]; LN229 [77]
		Melanoma	MM200, IgR3, SK‐MEL‐28, Mel‐FH [78]
Topoisomerase inhibitors	Doxorubicin	B‐cell lymphoma	Eμ‐Nras G12V;ectopic Bcl2 mouse model [34]
		Breast cancer	MCF‐7 [70, 79, 80]; Reporter Mouse model p16‐3MR‐MMTV‐PyMT grafts [37]; patients [79]
		Cervical carcinoma	HeLa [70]
		Colon cancer	HCT‐116, SW480 [70]; LS174T, HCA‐7 [79]
		Fibrosarcoma	HT1080 [70]
		Glioma	U251 [70]
		HCC	HepG2 [70]
		Larynx carcinoma	Hep‐2 [70]
		Lung cancer	NCI‐H460, A549 [81]
		Osteosarcoma	Saos2 [70]
		Ovarian cancer	A2780 [70, 79]
		Prostate cancer	LNCaP [70, 82]; DU145 [82]
	Daunorubicin	T‐cell lymphoma	Jurkat T cells [83]
	Etoposide	Fibrosarcoma	HT1080 [70]
		HCC	HepG2, U2OS [84]
	Irinotecan	Colorectal cancer	HCT‐116 [85, 86, 87]; LS174T [86, 87]
Microtubule inhibitors	Docetaxel	Prostate cancer	LNCaP, DU145 [82]; Pten pc−/− mouse model [88]
	Paclitaxel	Breast cancer	MCF‐7 [89, 90]; MDA‐MB‐231 [90]
		Colorectal cancer	HCT‐116 [90]
		Melanoma	A549 [90]
		Neuroblastoma	SH‐SY5Y [90]
Antimetabolites	Gemcitabine	Pancreatic carcinoma	Panc1 [91, 92]; Miapaca‐2 [92]
	Methotrexate	Breast cancer	MCF‐7 [93]
Cytotoxic antibiotic	Bleomycin	Lung cancer	A549 [94, 95]
Radiotherapy		Breast cancer	MCF‐7 [96]
		Glioma	U87 [97]